(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 20.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.49%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.23%.
Adma Biologics's revenue in 2026 is $509,864,000.On average, 6 Wall Street analysts forecast ADMA's revenue for 2026 to be $149,495,718,902, with the lowest ADMA revenue forecast at $141,302,553,427, and the highest ADMA revenue forecast at $155,751,264,480. On average, 6 Wall Street analysts forecast ADMA's revenue for 2027 to be $171,704,180,453, with the lowest ADMA revenue forecast at $141,279,376,155, and the highest ADMA revenue forecast at $190,162,559,476.
In 2028, ADMA is forecast to generate $204,618,223,711 in revenue, with the lowest revenue forecast at $160,562,866,043 and the highest revenue forecast at $230,219,837,810.